David
Santamaría Velilla
Institut d'Investigació Biomédica de Bellvitge
Barcelona, EspañaInstitut d'Investigació Biomédica de Bellvitge -ko ikertzaileekin lankidetzan egindako argitalpenak (6)
2024
-
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma
Cell Reports Medicine, Vol. 5, Núm. 8
-
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Nature Communications, Vol. 15, Núm. 1
2021
-
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer
Trends in Cancer, Vol. 7, Núm. 5, pp. 410-429
2020
-
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma
JCI Insight, Vol. 5, Núm. 15
2016
-
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma
Nature Medicine, Vol. 22, Núm. 3, pp. 270-277
2014
-
Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts
Cancer Research, Vol. 74, Núm. 21, pp. 5978-5988